Antibe Therapeutics closes public offering

On June 21, 2017, Antibe Therapeutics Inc. ("Antibe") announced the first closing of its previously announced marketed public offering of units for gross proceeds of approximately C$4,050,000, in which Antibe issued 40,498,999 units at a price of C$0.10 per unit. Each unit is comprised of one common share and one-half of one common share purchase warrant entitling the holder to purchase one common share at an exercise price of C$0.15 until June 21, 2020.

Antibe announced the second and final closing of the offering on August 18, 2017 in which it issued an additional 9,330,000 units for additional gross proceeds of approximately C$933,000. In total, through the offering, Antibe raised gross proceeds of C$4,983,000 from the sale of 49,830,000 units.

Bloom Burton Securities Inc., Dominick Inc., and Echelon Wealth Partners Inc. acted as co-agents for the offering.

Antibe is a diversified biotech with two best-in-class divisions in pain/inflammation and regenerative medicine.

Further information can be found on found on Antibe's website: first closing and second (final) closing.